

World Journal of *Gastroenterology*

World J Gastroenterol 2018 November 14; 24(42): 4721-4834



**EDITORIAL**

- 4721 Increased susceptibility of aging gastric mucosa to injury and delayed healing: Clinical implications
Tarnawski AS, Ahluwalia A

REVIEW

- 4728 Liver as a target of human immunodeficiency virus infection
Ganesan M, Poluektova LY, Kharbanda KK, Osna NA

MINIREVIEWS

- 4738 CXCL family of chemokines as prognostic or predictive biomarkers and possible drug targets in colorectal cancer
Cabrero-de las Heras S, Martínez-Balibrea E
- 4750 Gut microbiota in common elderly diseases affecting activities of daily living
Shimizu Y

ORIGINAL ARTICLE**Basic Study**

- 4759 Yiguanjian decoction enhances fetal liver stem/progenitor cell-mediated repair of liver cirrhosis through regulation of macrophage activation state
Xu Y, Fan WW, Xu W, Jiang SL, Chen GF, Liu C, Chen JM, Zhang H, Liu P, Mu YP
- 4773 Ubiquitin-like modifier activating enzyme 2 promotes cell migration and invasion through Wnt/ β -catenin signaling in gastric cancer
Li J, Sun X, He P, Liu WQ, Zou YB, Wang Q, Meng XW

Case Control Study

- 4787 Mode of delivery by an ulcerative colitis mother in a case of twins: Immunological differences in cord blood and placenta
Dunsmore G, Koleva P, Sutton RT, Ambrosio L, Huang V, Elahi S

Retrospective Cohort Study

- 4798 Increased end-stage renal disease risk in patients with inflammatory bowel disease: A nationwide population-based study
Park S, Chun J, Han KD, Soh H, Choi K, Kim JH, Lee J, Lee C, Im JP, Kim JS

Retrospective Study

- 4809 Prediction of colorectal tumor grade and invasion depth through narrow-band imaging scoring
Maeyama Y, Mitsuyama K, Noda T, Nagata S, Nagata T, Yoshioka S, Yoshida H, Mukasa M, Sumie H, Kawano H, Akiba J, Araki Y, Kakuma T, Tsuruta O, Torimura T

SYSTEMATIC REVIEWS

- 4821 Burden and outcomes for complex perianal fistulas in Crohn's disease: Systematic review
Panes J, Reinisch W, Rupniewska E, Khan S, Fornis J, Khalid JM, Bojic D, Patel H

ABOUT COVER

Editorial board member of *World Journal of Gastroenterology*, Kazuaki Inoue, MD, PhD, Associate Professor, Department of Internal Medicine, Division of Gastroenterology, Showa University Fujigaoka Hospital, Yokohama 227-8501, Japan

AIMS AND SCOPE

World Journal of Gastroenterology (*World J Gastroenterol*, *WJG*, print ISSN 1007-9327, online ISSN 2219-2840, DOI: 10.3748) is a peer-reviewed open access journal. *WJG* was established on October 1, 1995. It is published weekly on the 7th, 14th, 21st, and 28th each month. The *WJG* Editorial Board consists of 642 experts in gastroenterology and hepatology from 59 countries.

The primary task of *WJG* is to rapidly publish high-quality original articles, reviews, and commentaries in the fields of gastroenterology, hepatology, gastrointestinal endoscopy, gastrointestinal surgery, hepatobiliary surgery, gastrointestinal oncology, gastrointestinal radiation oncology, gastrointestinal imaging, gastrointestinal interventional therapy, gastrointestinal infectious diseases, gastrointestinal pharmacology, gastrointestinal pathophysiology, gastrointestinal pathology, evidence-based medicine in gastroenterology, pancreatology, gastrointestinal laboratory medicine, gastrointestinal molecular biology, gastrointestinal immunology, gastrointestinal microbiology, gastrointestinal genetics, gastrointestinal translational medicine, gastrointestinal diagnostics, and gastrointestinal therapeutics. *WJG* is dedicated to become an influential and prestigious journal in gastroenterology and hepatology, to promote the development of above disciplines, and to improve the diagnostic and therapeutic skill and expertise of clinicians.

INDEXING/ABSTRACTING

World Journal of Gastroenterology (*WJG*) is now indexed in Current Contents[®]/Clinical Medicine, Science Citation Index Expanded (also known as SciSearch[®]), Journal Citation Reports[®], Index Medicus, MEDLINE, PubMed, PubMed Central and Directory of Open Access Journals. The 2018 edition of Journal Citation Reports[®] cites the 2017 impact factor for *WJG* as 3.300 (5-year impact factor: 3.387), ranking *WJG* as 35th among 80 journals in gastroenterology and hepatology (quartile in category Q2).

EDITORS FOR THIS ISSUE

Responsible Assistant Editor: Xiang Li
Responsible Electronic Editor: Yan Huang
Proofing Editor-in-Chief: Lian-Sheng Ma

Responsible Science Editor: Rao-Yu Ma
Proofing Editorial Office Director: Ze-Mao Gong

NAME OF JOURNAL
World Journal of Gastroenterology

ISSN
ISSN 1007-9327 (print)
ISSN 2219-2840 (online)

LAUNCH DATE
October 1, 1995

FREQUENCY
Weekly

EDITORS-IN-CHIEF
Andrzej S Tarnawski, MD, PhD, DSc (Med),
Professor of Medicine, Chief Gastroenterology, VA
Long Beach Health Care System, University of California, Irvine, CA, 5901 E. Seventh Str., Long Beach, CA 90822, United States

EDITORIAL BOARD MEMBERS
All editorial board members resources online at <http://www.wjgnet.com/1007-9327/editorialboard.htm>

EDITORIAL OFFICE
Ze-Mao Gong, Director
World Journal of Gastroenterology
Baishideng Publishing Group Inc
7901 Stoneridge Drive, Suite 501,
Pleasanton, CA 94588, USA
Telephone: +1-925-2238242
Fax: +1-925-2238243
E-mail: editorialoffice@wjgnet.com
Help Desk: <http://www.f6publishing.com/helpdesk>
<http://www.wjgnet.com>

PUBLISHER
Baishideng Publishing Group Inc
7901 Stoneridge Drive, Suite 501,
Pleasanton, CA 94588, USA
Telephone: +1-925-2238242
Fax: +1-925-2238243
E-mail: bpgoffice@wjgnet.com
Help Desk: <http://www.f6publishing.com/helpdesk>
<http://www.wjgnet.com>

PUBLICATION DATE
November 14, 2018

COPYRIGHT
© 2018 Baishideng Publishing Group Inc. Articles published by this Open-Access journal are distributed under the terms of the Creative Commons Attribution Non-commercial License, which permits use, distribution, and reproduction in any medium, provided the original work is properly cited, the use is non commercial and is otherwise in compliance with the license.

SPECIAL STATEMENT
All articles published in journals owned by the Baishideng Publishing Group (BPG) represent the views and opinions of their authors, and not the views, opinions or policies of the BPG, except where otherwise explicitly indicated.

INSTRUCTIONS TO AUTHORS
Full instructions are available online at <http://www.wjgnet.com/bpg/gerinfo/204>

ONLINE SUBMISSION
<http://www.f6publishing.com>

CXC family of chemokines as prognostic or predictive biomarkers and possible drug targets in colorectal cancer

Sara Cabrero-de las Heras, Eva Martínez-Balibrea

Sara Cabrero-de las Heras, Eva Martínez-Balibrea, Program Against Cancer Therapeutic Resistance, Catalan Institute of Oncology, Germans Trias i Pujol health research institute, Badalona, Barcelona 08916, Catalunya, Spain

Sara Cabrero-de las Heras, Eva Martínez-Balibrea, Program of Predictive and Personalized Cancer Medicine, Germans Trias i Pujol health research institute, Badalona, Barcelona 08916, Catalunya, Spain

ORCID number: Sara Cabrero-de las Heras (0000-0002-9364-5371); Eva Martínez-Balibrea (0000-0002-4501-7100).

Author contributions: Both authors contributed equally to the conception and design of the study, literature review and analysis, drafting and critical revision and editing, and approval of the final version.

Supported by the Institute of Health Carlos III (ISCIII), No. PI16/01800 and PIE16/00011 (Co-funded by European Regional Development Fund "A way to make Europe").

Conflict-of-interest statement: The authors declare no potential conflicts of interest.

Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: <http://creativecommons.org/licenses/by-nc/4.0/>

Manuscript source: Invited manuscript

Correspondence to: Eva Martínez-Balibrea, PhD, Senior Scientist, Program Against Cancer Therapeutic Resistance, Catalan Institute of Oncology, Germans Trias i Pujol health research institute, Carretera de Can Ruti, camí de les escoles s/n, Badalona, Barcelona 08916, Catalunya, Spain. embalibrea@iconcologia.net

Telephone: +34-93-5543069

Fax: +34-93-4978654

Received: July 5, 2018

Peer-review started: July 5, 2018

First decision: August 25, 2018

Revised: September 27, 2018

Accepted: October 16, 2018

Article in press: October 16, 2018

Published online: November 14, 2018

Abstract

Colorectal cancer (CRC) is the third most common cancer in men and the second most common cancer in women, worldwide. In the early stages of the disease, biomarkers predicting early relapse would improve survival rates. In metastatic patients, the use of predictive biomarkers could potentially result in more personalized treatments and better outcomes. The CXC family of chemokines (CXCL1 to 17) are small (8 to 10 kDa) secreted proteins that attract neutrophils and lymphocytes. These chemokines signal through chemokine receptors (CXCR) 1 to 8. Several studies have reported that these chemokines and receptors have a role in either the promotion or inhibition of cancer, depending on their capacity to suppress or stimulate the action of the immune system, respectively. In general terms, activation of the CXCR1/CXCR2 pathway or the CXCR4/CXCR7 pathway is associated with tumor aggressiveness and poor prognosis; therefore, the specific inhibition of these receptors is a possible therapeutic strategy. On the other hand, the lesser known CXCR3 and CXCR5 axes are generally considered to be tumor suppressor signaling pathways, and their stimulation has been suggested as a way to fight cancer. These pathways have been studied in tumor tissues (using immunohistochemistry or measuring mRNA levels) or serum [using enzyme-linked immuno sorbent assay (ELISA) or multiplexing techniques], among other sample types. Common variants in genes encoding for the CXC chemokines have also been investigated as possible biomarkers of the disease. This review summarizes the

most recent findings on the role of CXC chemokines and their receptors in CRC and discusses their possible value as prognostic or predictive biomarkers as well as the possibility of targeting them as a therapeutic strategy.

Key words: Biomarkers; Treatment; Chemotherapy; Oxaliplatin; Irinotecan; Immunotherapy; Colorectal cancer; CXC chemokines; Immune system; Bevacizumab

© **The Author(s) 2018.** Published by Baishideng Publishing Group Inc. All rights reserved.

Core tip: The contribution of the immune system to the development and progression of cancer is now fully acknowledged. The specific action of the immune system depends on the type of immune cells that are recruited to the tumor sites. Chemokines from the CXC subfamily are released by tumor cells and cells within the tumor microenvironment, whereupon they attract cells with anti-tumor (*e.g.*, CD4⁺ and CD8⁺ lymphocytes) or pro-tumor activity (*e.g.*, myeloid-derived suppressor cells). Chemokines have been proposed as prognostic factors, as biomarkers of response to therapy and as drug targets. The present review addresses the most recent findings in the field.

Cabrero-de las Heras S, Martínez-Balibrea E. CXC family of chemokines as prognostic or predictive biomarkers and possible drug targets in colorectal cancer. *World J Gastroenterol* 2018; 24(42): 4738-4749 Available from: URL: <http://www.wjgnet.com/1007-9327/full/v24/i42/4738.htm> DOI: <http://dx.doi.org/10.3748/wjg.v24.i42.4738>

INTRODUCTION

Colorectal cancer (CRC) is the third most common type of cancer worldwide, representing approximately 10% of all diagnosed cancers, and it is the most frequent cause of cancer-related deaths^[1]. In Europe, the prognosis of localized disease is quite good; the 5-year overall survival rates are near 90%; however, in patients with regional or distant disease, these rates drop to 70% and down to 20%, respectively (source: Europacolon, <http://www.europacolon.com/colorectalcancer.php?Action=Colorectalcancer>)^[2]. One of the main reasons behind this poor survival rate is that, in almost all cases, tumors become resistant to therapy. Therefore, it is necessary to find useful and reliable predictive biomarkers that allow physicians to assign effective drugs specific to each case. In general, the current first-line treatment for metastatic CRC (mCRC) is based upon combinations of chemotherapy [fluoropyrimidines, oxaliplatin (OXA) and/or irinotecan], consisting of doublets (FOLFOX or FOLFIRI) or triplets (FOLFOXIRI) in specific cases, and rational molecularly targeting agents [anti-epidermal growth factor receptor (anti-EGFR), cetuximab or panitumumab; anti-vascular

endothelial growth factor (anti-VEGF), bevacizumab]^[3]. Mutations in the RAS and BRAF family of oncogenes are indicative of the inefficacy of anti-EGFR drugs and are the only predictive markers available currently^[4,5]. The recent classification of CRC into four molecular subtypes has shed light on the biology of this tumor. However, the clinical usefulness and application of this classification is still under discussion^[6,7].

It has been proposed that serum levels of certain chemokines may be used as predictive markers for the response to chemotherapy. The CXC family of chemokines and their receptors are crucial for inflammation and antitumor immunity, which are key factors in CRC progression. These small proteins are secreted not only by tumor cells but also by leukocytes, fibroblasts, endothelial cells and epithelial cells. They modulate tumor behavior by regulating angiogenesis, activating tumor-specific immune responses and directly stimulating tumor proliferation in an autocrine or paracrine fashion. The CXC family of chemokines and receptors have been associated with metastasis and resistance to treatment. Several studies have reported the expression of CXC chemokines and/or their receptors in tumors (in epithelial tumor cells, fibroblasts or infiltrating leukocytes) or in plasma/serum samples from CRC patients, and this expression has been associated with patient outcomes. Furthermore, the CXC genes are highly polymorphic, and certain genetic variants have been associated with prognosis and response to treatment. The aim of the present work is to review the literature and discuss the possible use of the CXC family of chemokines as predictive or prognostic markers in CRC (Table 1). We will focus on the main pathways that are activated after the appropriate chemokines bind to the receptors CXCR1, CXCR2, CXCR4, CXCR7, CXCR3, CXCR5, CXCR6 and CXCR8.

LITERATURE SEARCH

We established the work of Verbeke *et al.*^[8] as reference from which we searched the literature. We used PubMed as the primary source to find all of the articles published on this topic. The following keywords were employed in the search: chemokine/s, resistance, CRC, chemotherapy, 5 fluorouracil, OXA, cetuximab, bevacizumab, CXCL1, CXCL2, CXCL3, CXCL4, CXCL5, CXCL6, CXCL7, CXCL8, CXCL9, CXCL10, CXCL11, CXCL12, CXCL13, CXCL16, CXCL17, CXCR1, CXCR2, CXCR4, CXCR2 inhibitor, CXCR4 inhibitor, reparixin, cancer, repertaxin, and plerixafor. In addition to PubMed, we also performed a brief Google search for "Chemokine CRC".

THE CXC FAMILY OF CHEMOKINES

CXC chemokines are small proteins; CXC refers to the location of the two cysteine residues near the N-terminal, with the X representing any amino acid (cysteine-

Table 1 CXC chemokines as biomarkers

Biomarker	Cancer type	Expression	Where is it measured?	Treatment	Predictive value	Ref.
CXCL1/2	Breast cancer	High	Paraffin embedded tissue	Chemoresistance 5FU	Poor	[17]
CXCL1	CRC	High	Tumor and cell lines	OXA + CURCUMIN	Poor	[18]
CXCL1/8 CXCR2	CRC, Prostate cancer	High	Cell lines and <i>in vivo</i>	OXA + SCH-527123	Poor	[22,24]
CXCL8	CRC	Low	Serum	Chemotherapy + Bevacizumab	Good	[25,26]
CXCL8	Breast cancer	Polymorphism, TT genotype	Peripheral blood (DNA)	FOLFOX+ Bevacizumab <i>vs</i> FOLFOX alone	Good	[26]
CXCR1	CRC	Polymorphism	Whole blood (DNA)	OXA based + Bevacizumab	Good	[27]
CXCL7/8 CXCR2	CRC	High	mRNA levels tumors	Surgery + ady <i>vs</i> Ady alone	Poor	[28]
CXCR4	CRC	Colocalization-Lgr5	CRC cell lines and tumors		Poor	[35]
CXCR4	CRC	Colocalization-CD133	CRC cell lines and <i>in vivo</i>	5FU; 5FU and OXA	Poor	[36,38]
CXCR4-microbiota	CRC	High	<i>in vivo</i> and <i>in vitro</i>	Lipopolysaccharides	Poor	[39]
CXCL12-visfatin	CRC	Interaction	CRC cells		Poor	[40]
CXCR4	CRC	High	Paraffin embedded tissue	Patients that underwent hepatectomy	Poor	[41]
CXCR4	CRC	High	CRC cells	OXA or 5FU therapies including anti-VEGF	Poor	[46]
CXCL10-KRAS mut	CRC CMS2 and CMS3	Low	TCGA, tumors		Poor	[52]
CXCL10	CRC	High	CRC cells, tumors, <i>in vivo</i>		Good	[53]
CXCL10	CRC	Expression	Post-surgical localized CRC		Good	[53,56]
CXCR3	CRC	High	Protein levels in primary tumors		Poor	[57]
CXCL10/11	CRC	High	Serum		Poor	[58]
CXCL9/10	CRC	High	<i>in vivo</i>	Anthracyclines + STAT KO	Good	[60]
CXCL9/10/11	Rectal cancer	High	mRNA levels tumors	5FU + Radiotherapy	Good	[64,65]
CXCL4	CRC	High	<i>in vivo</i>	5FU	Poor	[66]
CXCL13 CXCR5	CRC	High	Plasma levels and paraffin embedded tissue		Poor	[69,70]
CXCL13-microbiota	CRC	High	Tumors		Good	[71]
CXCR5 ⁺ CD8 ⁺ T cell	CRC	Presence	Tumors		Good	[73]
CXCL13	CRC	Low	mRNA levels tumors		Good	[56,74]
CXCL16	CRC	High	Serum		Poor	[81]
CXCL17	CRC	High	mRNA levels cell lines and tumors		Poor	[87]

CRC: Colorectal cancer; OXA: Oxaliplatin; VEGF: Vascular endothelial growth factor; 5FU: 5-fluorouracil; KO: Knock out.

containing motif)^[9]. These chemokines can be sub-classified based on the presence or absence of the tripeptide motif (Glu-Leu-Arg at the NH2 terminus) as ELR⁺ or ELR⁻, respectively. The ELR⁺ chemokines are considered to be angiogenic, whereas the ELR⁻ chemokines are considered to be angiostatic^[10-12]. Nevertheless, contradictory results have been published, which we will discuss in the present review.

CXC chemokines are named according to their original function, and they also follow the standard nomenclature CXCLx, where the L stands for "ligand" and the x corresponds to a number (Table 2). To exert their function, chemokines bind to their cognate CXCR

which, in the majority of cases, is a 7-transmembrane G protein-coupled receptor^[13]. After binding, the receptors change their conformation and activate the coupled G protein, initiating the corresponding signaling pathway. Only a few of the CXCRs are atypical receptors, which are not coupled to a G protein but to beta-arrestins; these receptors include the atypical chemokine receptor 3 (ACKR3) also known as CXCR7^[14]. Certain chemokines can bind to more than one receptor and *vice versa*, as is the case for the promiscuous CXCR2^[15] (Table 2). After a given CXCL binds and activates the corresponding CXCR, the receptor is usually internalized through clathrin-mediated endocytosis for further degradation or recycling

Table 2 The CXC chemokines and their receptors

CXC ligand	Chemokine name	Receptor	ELR domain
CXCL1	Growth-regulated oncogene (Gro- α)	CXCR2	ELR ⁺
CXCL2	Growth-regulated oncogene (Gro- β)	CXCR2	ELR ⁺
CXCL3	Growth-regulated oncogene (Gro- γ)	CXCR2	ELR ⁺
CXCL4	Platelet factor-4 (PF-4)	CXCR3	ELR ⁻
CXCL5	Epithelial cell-derived neutrophil-activating peptide-78 (ENA-78)	CXCR2	ELR ⁺
CXCL6	Granulocyte chemotactic protein-2 (GCP-2)	CXCR1/2	ELR ⁺
CXCL7	Neutrophil-activating peptide-2 (NAP-2)	CXCR2	ELR ⁺
CXCL8	Interleukin-8 (IL-8)	CXCR1/2	ELR ⁺
CXCL9	Monokine induced by interferon- γ (Mig)	CXCR3	ELR ⁻
CXCL10	Inducible protein-10 (IP-10)	CXCR3	ELR ⁻
CXCL11	Interferon-inducible T cell alpha chemoattractant (I-TAC)	CXCR3/7	ELR ⁻
CXCL12	Stromal cell-derived factor-1 (SDF-1)	CXCR4/7	ELR ⁻
CXCL13	B cell-attracting chemokine-1 (BCA-1)	CXCR5	ELR ⁻
CXCL16	Scavenger receptor that binds phosphatidylserine and oxidized lipoprotein (SR-PSOX)	CXCR6	ELR ⁻
CXCL17	VEGF-correlated chemokine-1 (VCC-1)	CXCR8	ELR ⁺

VEGF: Vascular endothelial growth factor.




Figure 1 CXCL and CXCR regulatory mechanisms. Figure 1 illustrates CXCL binding to the CXCR located at the cellular membrane, internalizing and transducing the signal into the nucleus. CXCR internalization is usually followed by degradation or recycling to the plasma membrane.

to the plasma membrane^[16] (Figure 1).

Originally, the role of these chemokines and their receptors was associated with inflammatory processes wherein leukocytes accumulate in injured or infected tissues. Given that inflammation is a hallmark of cancer, it is not surprising that once in the nucleus, the CXC chemokines exert their activity through various pathways, such as tumor necrosis factor alpha (TNF- α)/nuclear factor κ B (NF- κ B) and protein kinase B (PKB/AKT)^[17,18]. These pathways are related to survival, proliferation, angiogenesis, pathological processes such as tumor growth and metastasis^[19,20], and even responses to anticancer treatments (Figure 2).

AXIS 1: CXCR1 AND CXCR2

The CXCR1/CXCR2 pathway is the most widely studied pathway in cancer. CXCL1, 2, 3 and 8 are proangiogenic and chemoattractive chemokines that all bind to the receptor CXCR2, for which CXCL1 has the highest

affinity. All four chemokines have been found to be upregulated in CRC^[21]. One of the most relevant studies demonstrating the role of CXCL1 and 2 in treatment resistance and metastasis was performed by the group of Joan Massagué. This group showed that CXCL1 and CXCL2 are overexpressed in breast cancer cells that are primed for survival in metastatic sites. These two chemokines attract CD11b⁺Gr1⁺ myeloid cells which, in turn, produce more chemokines and enhance cancer cell survival. Regarding chemoresistance, this group found that chemotherapeutic agents, such as 5 Fluorouracil (5FU), doxorubicin hydrochloride, cyclophosphamide monohydrate and paclitaxel trigger a stromal reaction, leading to TNF- α production. TNF- α increases CXCL1/2 expression *via* NF- κ B, which results in a feedback loop that promotes cancer cell survival^[17]. NF- κ B is a transcription factor that can be activated downstream of the PKB/AKT and mitogen-activated protein kinase (MAPK) signaling pathways. Increased activity of NF- κ B has been associated with the high expression of genes




Figure 2 CXCL and CXCR network in physiological and cancer conditions. A: The binding of CXCL to CXCR triggers the activation of signaling pathways, such as PKB/AKT and ERK/MAPK. Both pathways share NF- κ B as a downstream factor which, in the nucleus, promotes the transcription of the CXCLs. These pathways maintain the physiologic conditions inside the cell. B: In a cancer cell exposed to chemotherapy, the situation is different. The chemotherapeutic treatment promotes the hyperactivation of these pathways. As a result, the CXCLs are also more abundant, promoting an autocrine response and, further, a positive feedback loop. This response results in pathological processes, such as tumor growth and metastasis, and in resistance to anticancer treatments. PKB: Protein kinase B; ERK: Extracellular signal-regulated kinases; MAPK: Mitogen-activated protein kinase; NF- κ B: Nuclear factor κ B.

related to cancer cell survival, proliferation, angiogenesis, and also the development of resistance to anticancer drugs (Figure 2). As CXCL1 and 2 (and other chemokines that bind to CXCR1 and 2) can activate this pathway, it is not surprising that these chemokines play a role in chemoresistance and may also serve as predictive biomarkers in CRC.

For instance, we reported that CRC cells with acquired resistance to OXA exhibited high intracellular and secreted levels of CXCL1, 2 and 8, which was a consequence of the upregulated activation of NF- κ B in the resistant cells. Both the inhibition of NF- κ B with curcumin and the silencing of genes encoding for these chemokines led to a partial reversion of the resistance phenotype. The combination of curcumin and OXA was

especially synergistic in resistant cells. Moreover, in experiments with tissue explants derived from hepatic CRC metastasis, we determined that higher levels of CXCL1 led to higher sensitivity of explants to the combination of curcumin + OXA. Thus, the tumor or serum levels of CXCL1 may serve as a useful biomarker for OXA resistance and may be indicative of curcumin + OXA sensitivity^[18]. In another study, Ning *et al.*^[22] reported that CXCL8 mediated resistance to OXA in CRC cell lines through its binding to CXCR2 and AKT/MAPK/NF- κ B signaling. The gene silencing of CXCR2 sensitized cells to the platinum drug. Treatment of CRC cell lines with a CXCR2 antagonist (SCH-527123) resulted in decreased migration and invasion, and increased apoptosis, acting synergistically with OXA. Further work performed *in vivo*

demonstrated similar results^[23]. These results, together with those reported by Wilson *et al.*^[24] in prostate cancer cells, suggest that the levels of at least CXCL1 and 8 (and also CXCR2) can identify CRC patients who are unlikely to respond to OXA, who may be putative candidates for treatment with CXCR2 inhibitors in combination with this platinum agent.

The role of the CXCR1/CXCR2 pathway in the response and resistance to chemotherapy is not limited to OXA. Due to the role of these chemokines and receptors in promoting angiogenesis, it has been speculated that they can influence the response and resistance to antiangiogenic drugs. Two works reported that low serum levels of CXCL8 in mCRC patients treated with chemotherapy plus bevacizumab had better outcomes. First, in a short communication from Abajo *et al.*^[25], low levels of CXCL8 measured before treatment with bevacizumab, irinotecan and gemcitabine, were associated with better response rates in a small cohort of patients. This group also reported a general decrease in the levels of CXCL8 in post-treatment samples^[25]. In another study, Di Salvatore *et al.*^[26] analyzed the serum levels of CXCL8 in 120 RAS mutant patients treated with first-line 5FU + Leucovorin + OXA (known as FOLFOX) + bevacizumab. They found that low levels of CXCL8 were associated with longer progression-free (PFS) and overall survival (OS). The same group also studied a polymorphism (c-251T>A) in the CXCL8 gene and reported that the TT genotype was associated with longer PFS and OS in the aforementioned patients but not in another cohort that was treated only with FOLFOX. Interestingly, patients carrying the TT genotype had significantly lower serum levels of CXCL8 compared with patients with the AT or AA genotype^[26]. Another polymorphism (rs2234671) in the CXCR1 gene was found to be associated with the overall response rate in 132 mCRC patients treated with OXA-based chemotherapy plus bevacizumab. However, the authors did not provide a biological explanation underlying these results^[27]. Two methods of measuring chemokines and their receptors include the immunohistochemical staining of proteins in tumor tissues and the qPCR evaluation of mRNA levels. Using these techniques, Desurmont *et al.*^[28] determined that high levels of CXCR2 and its ligands, CXCL7 and 8, were associated with worse PFS and OS in CRC patients who underwent neoadjuvant chemotherapy (different schedules) followed by metastatic hepatectomy, but not in those who were treated with surgery alone. CXCR2 and CXCL7 mRNA levels were higher in metastasis from chemotherapy-treated patients compared to metastasis from patients who underwent surgery alone. These data suggest not only the prognostic value of CXCR2 (and CXCL7) but also its involvement in disease aggressiveness. Therefore, targeting the CXCR1/2-mediated signaling pathway has been suggested as a possible therapeutic approach for treating CRC and other tumors.

As the CXCR1/2-mediated signaling pathway is associated with inflammation, several studies have

described how the inhibition of CXCR1 or CXCR2 could potentially be used for preventive purposes^[29-31]. Notably, the study by Jamieson *et al.*^[31] showed that CXCR2 acts as a potent pro-tumorigenic CXCR which directs the recruitment of tumor-promoting leukocytes into tissues (including the intestines) during tumor-inducing and tumor-driven inflammation. Thus, the deletion or inhibition of this receptor led to the profound suppression of inflammation-driven and spontaneous tumorigenesis in a mouse model of colon cancer, suggesting that CXCR2 antagonists may have therapeutic and prophylactic potential in the treatment of cancer^[31]. Additionally, in the metastatic setting, it has been shown that treatment with inhibitors of this pathway may be a good strategy^[23,32-34]. Interestingly, the use of two different inhibitors against CXCR1 and 2 reduced the development of metastasis in mouse models but had no effect on primary tumors. This effect was due, in part, to the capacity of the inhibitors to abrogate neovascularization^[15].

AXIS 2: CXCR4 AND CXCR7

The CXCR4/CXCR7 pathway is activated after the binding of CXCL12 to CXCR4 or 7. Strikingly, although CXCL12 is an ELR⁺ chemokine, the activity of this pathway has been primarily associated with stemness, the development of metastasis and poor prognosis. CXCR4 has been shown to co-localize with CRC stem cell markers, such as Lgr5, CD133 and CD44, and this co-localization was associated with epithelial-mesenchymal transition (EMT) processes and resistance to therapy^[35-38]. Similar to CXCR1/2, the NF- κ B transcription factor appears to have a role in the induction of EMT. In this case, it has been shown that lipopolysaccharides can promote the migratory capacity of CRC *in vivo* and *in vitro* by inducing CXCR4 expression and EMT through NF- κ B signaling^[39]. Additionally, the link between obesity and CRC has been attributed to the interaction between the adipokine visfatin and CXCL12^[40]. CXCR4 expression appears to be increased in tumors compared with normal tissues and in metastasis compared with primary tumors. This increase is associated with poor prognosis, as shown in the work by Yopp *et al.*^[41]. This group assessed CXCR4 (among other factors) expression by immunohistochemical staining in 75 patients who underwent partial hepatectomy with curative intention and found that CXCR4 positivity was negatively associated with disease-specific and recurrence-free survival^[41]. This finding suggests the possibility of targeting CXCR4 for therapeutic purposes. A lentiviral vector carrying siRNA targeting CXCR4 was used in CRC cell lines and a mouse model; the result was a reduction in cell proliferation, migration and invasion and the formation of hepatic metastasis^[42]. Other researchers are attempting to exploit the membrane localization of CXCR4 to direct nanoparticles that recognize this receptor, facilitating their entry into the cells to deliver antineoplastic drugs^[43]. Specific inhibitors, such as plerixafor, have been identified as a possible therapy for CRC and are under investigation in several clinical trials

involving solid and non-solid tumors. Regardless of the strategy, it is important to take into account the biology of CXCR4 and 7. Two studies reported inconsistent regulation and effects between these two receptors. Romain *et al.*^[44] reported elevated levels of both receptors in late stage carcinomas compared to normal mucosa, colon polyps or early carcinomas. However, this group demonstrated that while CXCR4 expression was strongly induced by hypoxia-inducible factor 1 alpha (HIF-1 α), this was not the case of CXCR7. Moreover, the reduction of CXCR4 expression was associated with a decrease in AKT and extracellular signal-regulated kinases (ERK) activation which, was not observed for CXCR7. The authors conclude that CXCR4 is a more promising target compared to CXCR7 in CRC^[44]. Similarly, Heckmann and colleagues showed different (and partly antidromic) patterns of expression between CXCR7 and CXCR4 after stimulation with CXCL12 in colon cancer cells. CXCR4 overexpression was associated with increased levels of microRNA-217 and -218 in CXCR4-overexpressing cells, but this was not the case for the overexpression of CXCR7. Additionally, CXCR4 cells were more sensitive to 5FU compared with CXCR7 cells^[45]. Thus, the clinical application of CXCR4 antagonists, such as plerixafor, should be studied with caution. Finally, the relationship between this pathway and the resistance to treatment of CRC has also been studied. High levels of CXCR4 were found to be associated with resistance to all chemotherapeutic agents used (5FU, irinotecan and OXA), including anti-VEGF therapies. In SW1116 colon cancer cells with acquired resistance to OXA or 5FU, the expression of and signaling through CXCR4 was found to be associated with the chemoresistant phenotype. Specifically, the authors demonstrated that the ERK1/2/MAPK and phosphatidylinositol-3-kinases (PI3K)/AKT pathway was important in CXCR4-mediated chemoresistance^[46]. The effect of CXCR4 on resistance to OXA can be exploited therapeutically by using endostar, a modified endostatin. When endostar and OXA are administered together, they have a synergistic effect, primarily due to the reduction in CXCR4 levels^[47]. In two different orthotopic mouse models, treatment with anti-VEGFR2 therapy resulted in the upregulation of both CXCL12 and CXCR4. CXCR4-expressing immunosuppressive innate immune cells (Ly6low monocytes) were recruited to the tumor site upon treatment with anti-VEGFR2, which was abrogated after CXCR4 blockade^[48].

AXIS 3: CXCR3

The chemokines CXCL4, CXCL9, CXCL10 and CXCL11 are considered to exert an angiostatic effect through their binding to CXCR3, although CXCL11 can also bind to CXCR7^[49]. CXCR3 is found on peripheral blood activated T cells *in vitro* and on a significant fraction of circulating CD4⁺ and CD8⁺ T cells, B cells and natural killer (NK) cells, but not on monocytes or neutrophils^[50]. These chemokines are upregulated by interferon gamma (IFN- γ)

and, therefore, they have important roles in inflammatory diseases, such as ulcerative colitis^[50] and active pulmonary tuberculosis^[51]. However, the infiltration of activated CD4⁺ and CD8⁺ T cells in tumors is considered to be a good prognostic factor; consequently, most of the research on the expression of these chemokines or their receptors in the context of CRC is focused in that direction. An interesting study by Lal *et al.*^[52] suggests that KRAS mutations are associated with reduced levels of CXCL10 and with the suppression of cytotoxic T cells, neutrophils and the IFN- γ pathway, especially in CRC consensus molecular subtype (CMS) 2 and CMS3. Other studies also reported the potential of these chemokines as good prognostic factors, primarily because of their association with the high infiltration of CD8⁺ T and CD4⁺ T helper 1 (Th1) effector cells^[53-55]. Mice injected with colonic tumor cells overexpressing CXCL10 were protected against metastasis development^[53]. Two independent studies demonstrated the post-surgical positive prognostic value of CXCL10 expression in localized colon cancer^[53,56]. Specifically, in the study by Agesen *et al.*^[57], CXCL10 levels were part of a 13-gene expression classifier called ColoGuideEX for the prognosis prediction in stage II CRC. Interestingly, some authors have reported the opposite results. For instance, a high level of CXCR3 protein expression in primary CRC tumors was shown to be indicative of a poor prognosis^[57]. In another study, the authors investigated the molecular factors underlying the poor prognosis of CRC tumor neuroendocrine differentiation and found that neuroendocrine-like cells secreted high levels of CXCL10 and CXCL11 which, in turn, promoted the recruitment of tumor-associated macrophages, thereby promoting the proliferation and invasion of CRC cells and leading to a poor prognosis^[58].

Taken together, these findings appear to indicate that targeting CXCR3 or its ligands would not be an effective therapeutic strategy against CRC. However, some authors have speculated otherwise about the possibility of enhancing this pathway indirectly. It is worth commenting on three different papers that address three different strategies. First, Brackett *et al.*^[59] used a Toll-like receptor 5 (TLR5) agonist called entolimod in a murine mCRC model. This group found that entolimod induced the expression of CXCL9 and CXCL10 in tumors which, in turn, led to the recruitment of CXCR3⁺ NK cells to the liver, thereby activating dendritic cells (DCs) and stimulating the CD8⁺ T cell response. Consequently, the drug exerted an anti-metastatic effect and a tumor-specific and durable immune memory^[59]. Second, Yang *et al.*^[60] studied the effect of signal transducer and activator transcription 3 (STAT3) inhibition in combination with immunogenic chemotherapy (anthracyclines). This group showed that, when injected in mice, STAT3 KO cells developed tumors with higher infiltration of DCs and cytotoxic T cells after treatment with anthracyclines. These tumors also displayed higher levels of CXCL9 and 10. Consequently, STAT3 inhibition improved the outcome of chemotherapy-treated mice by synergizing with immunogenic chemotherapy^[60]. Another interesting

approach involved the depletion of regulatory T cells (Treg) in mice bearing CRC tumors. This depletion was associated with an increase in T cell infiltration and proliferation and an increase in CXCL9 and 10, which led to the accumulation of CXCR3⁺ T cells and the increased mRNA expression of IFN- γ , which suggests Treg cell targeting as a possible anti-tumor immunotherapy^[61]. It is important to note that some studies have indicated that CXCR3 targeting may be a good strategy against CRC cancer^[62,63].

Finally, high mRNA levels of CXCL9 and 11^[64] as well as CXCL10^[64,65] appear to be associated with the response to neoadjuvant chemotherapy (5FU) plus radiotherapy in patients with locally advanced rectal cancer; on the other hand, CXCL4 was shown to be upregulated after treatment with 5FU, which was associated with accelerated growth *in vivo*^[66]. These studies suggest the possibility of using members of this pathway as predictive biomarkers.

AXIS 4: MISCELLANY

Finally, it is worth commenting on the lesser known chemokines CXCL13, 16 and 17. Similar to that of the previously mentioned chemokines, the CXCL13-CXCR5 axis is involved in regulating lymphocyte migration and promoting inflammation^[67]. However, the role of this axis in promoting or inhibiting tumor development or progression is not clear, as the current articles report contradictory results. Zhu *et al.*^[68] reported that this pathway promotes the growth, migration and invasion of colon cancer cells, likely through the PI3K/AKT pathway. Accordingly, high plasma levels of CXCL13 and positive immunohistochemical staining of CXCL13 and CXCR5 in tumors from CRC patients were associated with clinical and pathological characteristics typically related with a worse prognosis^[69,70]. In contrast, high levels of CXCL13 in colorectal tumors have also been shown to be associated with the infiltration of follicular Th and B cells and, consequently, with a better prognosis. Cremonesi *et al.*^[71] attributed the increase in CXCL13 levels to the presence of gut microbiota, whereas in the work of Bindea *et al.*^[72], genomic instability affected CXCL13 expression, which led to alterations in T and B cell infiltration and clinical outcomes. In addition, it appears that a significant CD8⁺ T cell subset in colorectal tumors that are CXCR5⁺ potentially contribute to anti-tumor activity^[73]. Not surprisingly, low levels of CXCL13 have been reported as a negative prognostic factor in CRC patients^[56,74]. These contradictory results may be affected by several factors, including tumor stage, treatment, molecular subtype and microsatellite instability.

CXCR6 is expressed on the surface of CD4⁺ T cells, CD8⁺ T cells, NK cells and plasma cells and is responsible for inducing the chemotactic migration of these cells to inflamed tissues. The ligand of CXCR6, CXCL16, has two forms, the trans-membrane (TM) form and the soluble(s) form. TM-CXCL16 is expressed on macrophages, DCs, monocytes, and B cells where it functions as a cell

adhesion molecule for cells that express CXCR6^[75]. TM-CXCL16 is also a novel scavenger receptor that binds to phosphatidylserine and oxidized lipoprotein. In the membrane, this chemokine is cleaved by the disintegrin-like metalloproteinases ADAM10 and ADAM17, producing fragments that are released outside the cells^[76]. sCXCL16 functions as a chemotactic factor for CXCR6-expressing Th1, T cells and NK cells. Interestingly, soluble CXCL16 can promote angiogenesis in human umbilical vein endothelial cells^[77]. Again, given its capacity to promote tumor immunity, many of the published works describe CXCL16 as a positive prognostic factor^[78-80]. On the other hand, Matsushita *et al.*^[81] reported that CRC patients had higher levels of CXCL16 in the serum compared to healthy controls, and these levels increased with tumor stage and were correlated with poor survival. In patients with localized disease, higher serum levels of CXCL16 were associated with a higher probability of metachronous liver recurrence and worse survival. *In vitro*, treatment with recombinant CXCL16 promoted cell growth, migration, invasion and EMT^[81]. Thus, the exact role of CXCL16 in CRC warrants further investigation.

Finally, CXCL17 is a 119-amino acid CXC chemokine that binds specifically to CXCR8^[82,83]. This chemokine is expressed in breast and colon cancer and acts as a chemoattractant for monocytes, macrophages and mature and immature DCs, thereby playing an important role in angiogenesis^[84-86]. CXCL17 expression is co-regulated with VEGF expression^[82,84] and can attract neutrophils to tumor sites and promote tumorigenesis through angiogenesis in mouse models^[86]. Very little is known about the role of CXCL17 in CRC. Ohlsson *et al.*^[87] reported high mRNA levels of CXCL17 in several CRC cell lines as well as very high mRNA and protein levels of CXCL17 in primary CRC tumors compared to normal colon tissue. CXCL17-positive cells measured by immunofluorescence and immunohistochemistry were significantly more abundant in colon cancer tissues (80%) compared with the controls (normal colon samples from proximal or distal resection margin). Interestingly, CXCL17 was more abundant in tumor epithelial cells (17.2%) in comparison with tumor stromal cells (2.7%), and CXCL17 mRNA levels were correlated with the myeloid cell marker CD86, which is primarily expressed in antigen presenting cells (APCs), suggesting that this chemokine may contribute to the infiltration of APCs into the tumor^[87]. Taken together, these findings indicate that the high expression of CXCL17 in CRC may be an indicator of poor prognosis in colon cancer, although further studies are warranted to elucidate the exact role of this chemokine in this malignancy.

In summary, very little information is available on the role of these less-known chemokines in CRC development or response to treatment.

CONCLUSION

The importance of the immune system in the surveillance, prognosis and treatment of cancer is undeniable.

The recent development of immunotherapies and the rapidness of their application to the clinics for several tumor types demonstrate the possibilities of exploiting the immune system as a target for drug development. Moreover, the recent publication of the international validation of the consensus Immunoscore^[88] as a reliable tool to classify colon cancer and to prognosticate its outcome also reveals the utility of using immune factors [in this case, total tumor-infiltrating T cell (CD3⁺) and cytotoxic T cell counts (CD8⁺)] as biomarkers. Therefore, other immune system-related factors thought to be important in cancer development and/or progression may also serve as prognostic and/or predictive biomarkers. Specially, those soluble factors that are released from tumor cells and are involved in the attraction of tumor-promoting or -killing cells are interesting candidates. In the present review, we have described the potential utility of chemokines from the CXC family as biomarkers of response and prognosis in CRC. Moreover, as these chemokines exert their function through binding to membrane receptors, these receptors also appear to be excellent drug targets. Some challenges still need to be overcome. First, some researchers have doubts about the systemic value of a factor that exerts its function locally. Second, due to certain contradictory reports, a deeper knowledge of the exact roles of each chemokine and its receptor(s) is urgently needed. Nevertheless, we are convinced that in the following years, these small secreted proteins will have a large role in predictive and personalized cancer medicine.

REFERENCES

- 1 **DeSantis CE**, Lin CC, Mariotto AB, Siegel RL, Stein KD, Kramer JL, Alteri R, Robbins AS, Jemal A. Cancer treatment and survivorship statistics, 2014. *CA Cancer J Clin* 2014; **64**: 252-271 [PMID: 24890451 DOI: 10.3322/caac.21235]
- 2 **Welch HG**, Robertson DJ. Colorectal Cancer on the Decline--Why Screening Can't Explain It All. *N Engl J Med* 2016; **374**: 1605-1607 [PMID: 27119236 DOI: 10.1056/NEJMp1600448]
- 3 **Van Cutsem E**, Cervantes A, Adam R, Sobrero A, Van Krieken JH, Aderka D, Aranda Aguilar E, Bardelli A, Benson A, Bodoky G, Ciardiello F, D'Hoore A, Diaz-Rubio E, Douillard JY, Ducreux M, Falcone A, Grothey A, Gruenberger T, Haustermans K, Heinemann V, Hoff P, Köhne CH, Labianca R, Laurent-Puig P, Ma B, Maughan T, Muro K, Normanno N, Österlund P, Oyen WJ, Papamichael D, Pentheroudakis G, Pfeiffer P, Price TJ, Punt C, Ricke J, Roth A, Salazar R, Scheithauer W, Schmoll HJ, Tabernero J, Taïeb J, Tejpar S, Wasan H, Yoshino T, Zaanen A, Arnold D. ESMO consensus guidelines for the management of patients with metastatic colorectal cancer. *Ann Oncol* 2016; **27**: 1386-1422 [PMID: 27380959 DOI: 10.1093/annonc/mdw235]
- 4 **Cremolini C**, Schirripa M, Antoniotti C, Moretto R, Salvatore L, Masi G, Falcone A, Loupakis F. First-line chemotherapy for mCRC—a review and evidence-based algorithm. *Nat Rev Clin Oncol* 2015; **12**: 607-619 [PMID: 26215044 DOI: 10.1038/nrclinonc.2015.129]
- 5 **Dienstmann R**, Salazar R, Tabernero J. Overcoming Resistance to Anti-EGFR Therapy in Colorectal Cancer. *Am Soc Clin Oncol Educ Book* 2015; : e149-e156 [PMID: 25993166 DOI: 10.14694/EdBook_AM.2015.35.e149]
- 6 **Guinney J**, Dienstmann R, Wang X, de Reyniès A, Schlicker A, Soneson C, Marisa L, Roepman P, Nyamundanda G, Angelino P, Bot BM, Morris JS, Simon IM, Gerster S, Fessler E, De Sousa E Melo F, Missiaglia E, Ramay H, Barras D, Homicsko K, Maru D, Manyam GC, Broom B, Boige V, Perez-Villamil B, Laderas T, Salazar R, Gray JW, Hanahan D, Tabernero J, Bernards R, Friend SH, Laurent-Puig P, Medema JP, Sadanandam A, Wessels L, Delorenzi M, Kopetz S, Vermeulen L, Tejpar S. The consensus molecular subtypes of colorectal cancer. *Nat Med* 2015; **21**: 1350-1356 [PMID: 26457759 DOI: 10.1038/nm.3967]
- 7 **Dienstmann R**, Vermeulen L, Guinney J, Kopetz S, Tejpar S, Tabernero J. Consensus molecular subtypes and the evolution of precision medicine in colorectal cancer. *Nat Rev Cancer* 2017; **17**: 79-92 [PMID: 28050011 DOI: 10.1038/nrc.2016.126]
- 8 **Verbeke H**, Geboes K, Van Damme J, Struyf S. The role of CXC chemokines in the transition of chronic inflammation to esophageal and gastric cancer. *Biochim Biophys Acta* 2012; **1825**: 117-129 [PMID: 22079531 DOI: 10.1016/j.bbcan.2011.10.008]
- 9 **Moser B**, Wolf M, Walz A, Loetscher P. Chemokines: multiple levels of leukocyte migration control. *Trends Immunol* 2004; **25**: 75-84 [PMID: 15102366 DOI: 10.1016/j.it.2003.12.005]
- 10 **Bizzarri C**, Beccari AR, Bertini R, Cavicchia MR, Giorgini S, Allegretti M. ELR+ CXC chemokines and their receptors (CXC chemokine receptor 1 and CXC chemokine receptor 2) as new therapeutic targets. *Pharmacol Ther* 2006; **112**: 139-149 [PMID: 16720046 DOI: 10.1016/j.pharmthera.2006.04.002]
- 11 **Koizumi K**, Hojo S, Akashi T, Yasumoto K, Saiki I. Chemokine receptors in cancer metastasis and cancer cell-derived chemokines in host immune response. *Cancer Sci* 2007; **98**: 1652-1658 [PMID: 17894551 DOI: 10.1111/j.1349-7006.2007.00606.x]
- 12 **Vandercappellen J**, Van Damme J, Struyf S. The role of CXC chemokines and their receptors in cancer. *Cancer Lett* 2008; **267**: 226-244 [PMID: 18579287 DOI: 10.1016/j.canlet.2008.04.050]
- 13 **Rajagopal S**, Rajagopal K, Lefkowitz RJ. Teaching old receptors new tricks: biasing seven-transmembrane receptors. *Nat Rev Drug Discov* 2010; **9**: 373-386 [PMID: 20431569 DOI: 10.1038/nrd3024]
- 14 **Bachelier F**, Graham GJ, Locati M, Mantovani A, Murphy PM, Nibbs R, Rot A, Sozzani S, Thelen M. New nomenclature for atypical chemokine receptors. *Nat Immunol* 2014; **15**: 207-208 [PMID: 24549061 DOI: 10.1038/ni.2812]
- 15 **Varney ML**, Singh S, Li A, Mayer-Ezell R, Bond R, Singh RK. Small molecule antagonists for CXCR2 and CXCR1 inhibit human colon cancer liver metastases. *Cancer Lett* 2011; **300**: 180-188 [PMID: 21035946 DOI: 10.1016/j.canlet.2010.10.004]
- 16 **Marchese A**. Endocytic trafficking of chemokine receptors. *Curr Opin Cell Biol* 2014; **27**: 72-77 [PMID: 24680433 DOI: 10.1016/j.cceb.2013.11.011]
- 17 **Acharyya S**, Oskarsson T, Vanharanta S, Malladi S, Kim J, Morris PG, Manova-Todorova K, Leversha M, Hogg N, Seshan VE, Norton L, Brogi E, Massagué J. A CXCL1 paracrine network links cancer chemoresistance and metastasis. *Cell* 2012; **150**: 165-178 [PMID: 22770218 DOI: 10.1016/j.cell.2012.04.042]
- 18 **Ruiz de Porras V**, Bystrup S, Martínez-Cardús A, Pluvinet R, Sumoy L, Howells L, James MI, Iwuiji C, Manzano JL, Layos L, Bugés C, Abad A, Martínez-Balibrea E. Curcumin mediates oxaliplatin-acquired resistance reversion in colorectal cancer cell lines through modulation of CXC-Chemokine/NF-κB signalling pathway. *Sci Rep* 2016; **6**: 24675 [PMID: 27091625 DOI: 10.1038/srep24675]
- 19 **Speyer CL**, Ward PA. Role of endothelial chemokines and their receptors during inflammation. *J Invest Surg* 2011; **24**: 18-27 [PMID: 21275526 DOI: 10.3109/08941939.2010.521232]
- 20 **Raman D**, Baugher PJ, Thu YM, Richmond A. Role of chemokines in tumor growth. *Cancer Lett* 2007; **256**: 137-165 [PMID: 17629396 DOI: 10.1016/j.canlet.2007.05.013]
- 21 **Bandapalli OR**, Ehrmann F, Ehemann V, Gaida M, Macher-Goeppinger S, Wente M, Schirmacher P, Brand K. Down-regulation of CXCL1 inhibits tumor growth in colorectal liver metastasis. *Cytokine* 2012; **57**: 46-53 [PMID: 22129625 DOI: 10.1016/j.cyto.2011.10.019]
- 22 **Ning Y**, Manegold PC, Hong YK, Zhang W, Pohl A, Lurje G,

- Winder T, Yang D, LaBonte MJ, Wilson PM, Ladner RD, Lenz HJ. Interleukin-8 is associated with proliferation, migration, angiogenesis and chemosensitivity in vitro and in vivo in colon cancer cell line models. *Int J Cancer* 2011; **128**: 2038-2049 [PMID: 20648559 DOI: 10.1002/ijc.25562]
- 23 **Ning Y**, Labonte MJ, Zhang W, Bohanes PO, Gerger A, Yang D, Benhaim L, Paez D, Rosenberg DO, Nagulapalli Venkata KC, Louie SG, Petasis NA, Ladner RD, Lenz HJ. The CXCR2 antagonist, SCH-527123, shows antitumor activity and sensitizes cells to oxaliplatin in preclinical colon cancer models. *Mol Cancer Ther* 2012; **11**: 1353-1364 [PMID: 22391039 DOI: 10.1158/1535-7163.MCT-11-0915]
 - 24 **Wilson C**, Purcell C, Seaton A, Oladipo O, Maxwell PJ, O'Sullivan JM, Wilson RH, Johnston PG, Waugh DJ. Chemotherapy-induced CXC-chemokine/CXC-chemokine receptor signaling in metastatic prostate cancer cells confers resistance to oxaliplatin through potentiation of nuclear factor-kappaB transcription and evasion of apoptosis. *J Pharmacol Exp Ther* 2008; **327**: 746-759 [PMID: 18780829 DOI: 10.1124/jpet.108.143826]
 - 25 **Abajo A**, Boni V, Lopez I, Gonzalez-Huarriz M, Bitarte N, Rodriguez J, Zarate R, Bandres E, Garcia-Foncillas J. Identification of predictive circulating biomarkers of bevacizumab-containing regimen efficacy in pre-treated metastatic colorectal cancer patients. *Br J Cancer* 2012; **107**: 287-290 [PMID: 22699823 DOI: 10.1038/bjc.2012.242]
 - 26 **Di Salvatore M**, Pietrantonio F, Orlandi A, Del Re M, Berenato R, Rossi E, Caporale M, Guarino D, Martinetti A, Basso M, Mennitto R, Santonocito C, Mennitto A, Schinzari G, Bossi I, Capoluongo E, Danesi R, de Braud F, Barone C. IL-8 and eNOS polymorphisms predict bevacizumab-based first line treatment outcomes in RAS mutant metastatic colorectal cancer patients. *Oncotarget* 2017; **8**: 16887-16898 [PMID: 28129643 DOI: 10.18632/oncotarget.14810]
 - 27 **Gerger A**, El-Khoueiry A, Zhang W, Yang D, Singh H, Bohanes P, Ning Y, Winder T, Labonte MJ, Wilson PM, Benhaim L, Paez D, El-Khoueiry R, Absenger G, Lenz HJ. Pharmacogenetic angiogenesis profiling for first-line Bevacizumab plus oxaliplatin-based chemotherapy in patients with metastatic colorectal cancer. *Clin Cancer Res* 2011; **17**: 5783-5792 [PMID: 21791631 DOI: 10.1158/1078-0432.CCR-11-1115]
 - 28 **Desurmont T**, Skrypek N, Duhamel A, Jonckheere N, Millet G, Leteurtre E, Gosset P, Duchene B, Ramdane N, Hebbar M, Van Seuning I, Pruvot FR, Huet G, Truant S. Overexpression of chemokine receptor CXCR2 and ligand CXCL7 in liver metastases from colon cancer is correlated to shorter disease-free and overall survival. *Cancer Sci* 2015; **106**: 262-269 [PMID: 25580640 DOI: 10.1111/cas.12603]
 - 29 **Triner D**, Xue X, Schwartz AJ, Jung I, Colacino JA, Shah YM. Epithelial Hypoxia-Inducible Factor 2 α Facilitates the Progression of Colon Tumors through Recruiting Neutrophils. *Mol Cell Biol* 2017; **37**: [PMID: 27956697 DOI: 10.1128/MCB.00481-16]
 - 30 **Lee YS**, Choi D, Kim NY, Yang S, Jung E, Hong M, Yang D, Lenz HJ, Hong YK. CXCR2 inhibition enhances sulindac-mediated suppression of colon cancer development. *Int J Cancer* 2014; **135**: 232-237 [PMID: 24338666 DOI: 10.1002/ijc.28668]
 - 31 **Jamieson T**, Clarke M, Steele CW, Samuel MS, Neumann J, Jung A, Huels D, Olson MF, Das S, Nibbs RJ, Sansom OJ. Inhibition of CXCR2 profoundly suppresses inflammation-driven and spontaneous tumorigenesis. *J Clin Invest* 2012; **122**: 3127-3144 [PMID: 22922255 DOI: 10.1172/JCI61067]
 - 32 **Kawamura M**, Toiyama Y, Tanaka K, Saigusa S, Okugawa Y, Hiro J, Uchida K, Mohri Y, Inoue Y, Kusunoki M. CXCL5, a promoter of cell proliferation, migration and invasion, is a novel serum prognostic marker in patients with colorectal cancer. *Eur J Cancer* 2012; **48**: 2244-2251 [PMID: 22197219 DOI: 10.1016/j.ejca.2011.11.032]
 - 33 **Yamamoto M**, Kikuchi H, Ohta M, Kawabata T, Hiramatsu Y, Kondo K, Baba M, Kamiya K, Tanaka T, Kitagawa M, Konno H. TSU68 prevents liver metastasis of colon cancer xenografts by modulating the premetastatic niche. *Cancer Res* 2008; **68**: 9754-9762 [PMID: 19047154 DOI: 10.1158/0008-5472.CAN-08-1748]
 - 34 **Lin SC**, Hsiao KY, Chang N, Hou PC, Tsai SJ. Loss of dual-specificity phosphatase-2 promotes angiogenesis and metastasis via up-regulation of interleukin-8 in colon cancer. *J Pathol* 2017; **241**: 638-648 [PMID: 28026024 DOI: 10.1002/path.4868]
 - 35 **Wu W**, Cao J, Ji Z, Wang J, Jiang T, Ding H. Co-expression of Lgr5 and CXCR4 characterizes cancer stem-like cells of colorectal cancer. *Oncotarget* 2016; **7**: 81144-81155 [PMID: 27835894 DOI: 10.18632/oncotarget.13214]
 - 36 **Zhu P**, Zhao N, Sheng D, Hou J, Hao C, Yang X, Zhu B, Zhang S, Han Z, Wei L, Zhang L. Inhibition of Growth and Metastasis of Colon Cancer by Delivering 5-Fluorouracil-loaded Pluronic P85 Copolymer Micelles. *Sci Rep* 2016; **6**: 20896 [PMID: 26864651 DOI: 10.1038/srep20896]
 - 37 **Cutler MJ**, Lowthers EL, Richard CL, Hajducek DM, Spagnuolo PA, Blay J. Chemotherapeutic agents attenuate CXCL12-mediated migration of colon cancer cells by selecting for CXCR4-negative cells and increasing peptidase CD26. *BMC Cancer* 2015; **15**: 882 [PMID: 26552750 DOI: 10.1186/s12885-015-1702-2]
 - 38 **Margolin DA**, Silinsky J, Grimes C, Spencer N, Aycock M, Green H, Cordova J, Davis NK, Driscoll T, Li L. Lymph node stromal cells enhance drug-resistant colon cancer cell tumor formation through SDF-1 α /CXCR4 paracrine signaling. *Neoplasia* 2011; **13**: 874-886 [PMID: 21969820]
 - 39 **Liu WT**, Jing YY, Yan F, Han ZP, Lai FB, Zeng JX, Yu GF, Fan QM, Li R, Zhao QD, Wu MC, Wei LX. LPS-induced CXCR4-dependent migratory properties and a mesenchymal-like phenotype of colorectal cancer cells. *Cell Adh Migr* 2017; **11**: 13-23 [PMID: 26745593 DOI: 10.1080/19336918.2015.1134404]
 - 40 **Huang WS**, Chen CN, Sze CI, Teng CC. Visfatin induces stromal cell-derived factor-1 expression by β 1 integrin signaling in colorectal cancer cells. *J Cell Physiol* 2013; **228**: 1017-1024 [PMID: 23042611 DOI: 10.1002/jcp.24248]
 - 41 **Yopp AC**, Shia J, Butte JM, Allen PJ, Fong Y, Jarnagin WR, DeMatteo RP, D'Angelica MI. CXCR4 expression predicts patient outcome and recurrence patterns after hepatic resection for colorectal liver metastases. *Ann Surg Oncol* 2012; **19** Suppl 3: S339-S346 [PMID: 21584832 DOI: 10.1245/s10434-011-1774-4]
 - 42 **Wang TB**, Hu BG, Liu DW, Shi HP, Dong WG. The influence of lentivirus-mediated CXCR4 RNA interference on hepatic metastasis of colorectal cancer. *Int J Oncol* 2014; **44**: 1861-1869 [PMID: 24647809 DOI: 10.3892/ijo.2014.2348]
 - 43 **Unzueta U**, Céspedes MV, Ferrer-Miralles N, Casanova I, Cedano J, Corchero JL, Domingo-Espín J, Villaverde A, Mangues R, Vázquez E. Intracellular CXCR4⁺ cell targeting with T22-empowered protein-only nanoparticles. *Int J Nanomedicine* 2012; **7**: 4533-4544 [PMID: 22923991 DOI: 10.2147/IJN.S34450]
 - 44 **Romain B**, Hachet-Haas M, Rohr S, Brigand C, Galzi JL, Gaub MP, Penebreach E, Guenot D. Hypoxia differentially regulated CXCR4 and CXCR7 signaling in colon cancer. *Mol Cancer* 2014; **13**: 58 [PMID: 24629239 DOI: 10.1186/1476-4598-13-58]
 - 45 **Heckmann D**, Maier P, Laufs S, Li L, Sleeman JP, Trunk MJ, Leupold JH, Wenz F, Zeller WJ, Fruehauf S, Allgayer H. The disparate twins: a comparative study of CXCR4 and CXCR7 in SDF-1 α -induced gene expression, invasion and chemosensitivity of colon cancer. *Clin Cancer Res* 2014; **20**: 604-616 [PMID: 24255072 DOI: 10.1158/1078-0432.CCR-13-0582]
 - 46 **Huang WS**, Hsieh MC, Huang CY, Kuo YH, Tung SY, Shen CH, Hsieh YY, Teng CC, Lee KF, Chen TC, Lee KC, Kuo HC. The Association of CXC Receptor 4 Mediated Signaling Pathway with Oxaliplatin-Resistant Human Colorectal Cancer Cells. *PLoS One* 2016; **11**: e0159927 [PMID: 27668882 DOI: 10.1371/journal.pone.0159927]
 - 47 **Jin F**, Ji H, Jia C, Brockmeier U, Hermann DM, Metzen E, Zhu Y, Chi B. Synergistic antitumor effects of endostar in combination with oxaliplatin via inhibition of HIF and CXCR4 in the colorectal cell line SW1116. *PLoS One* 2012; **7**: e47161 [PMID: 23071744 DOI: 10.1371/journal.pone.0047161]
 - 48 **Jung K**, Heishi T, Incio J, Huang Y, Beech EY, Pinter M, Ho WW, Kawaguchi K, Rahbari NN, Chung E, Kim JK, Clark JW,

- Willett CG, Yun SH, Luster AD, Padera TP, Jain RK, Fukumura D. Targeting CXCR4-dependent immunosuppressive Ly6C^{low} monocytes improves antiangiogenic therapy in colorectal cancer. *Proc Natl Acad Sci USA* 2017; **114**: 10455-10460 [PMID: 28900008 DOI: 10.1073/pnas.1710754114]
- 49 **Burns JM**, Summers BC, Wang Y, Melikian A, Berahovich R, Miao Z, Penfold ME, Sunshine MJ, Littman DR, Kuo CJ, Wei K, McMaster BE, Wright K, Howard MC, Schall TJ. A novel chemokine receptor for SDF-1 and I-TAC involved in cell survival, cell adhesion, and tumor development. *J Exp Med* 2006; **203**: 2201-2213 [PMID: 16940167 DOI: 10.1084/jem.20052144]
- 50 **Qin S**, Rottman JB, Myers P, Kassam N, Weinblatt M, Loetscher M, Koch AE, Moser B, Mackay CR. The chemokine receptors CXCR3 and CCR5 mark subsets of T cells associated with certain inflammatory reactions. *J Clin Invest* 1998; **101**: 746-754 [PMID: 9466968 DOI: 10.1172/JCI1422]
- 51 **Sauty A**, Dziejman M, Taha RA, Iarossi AS, Neote K, Garcia-Zepeda EA, Hamid Q, Luster AD. The T cell-specific CXC chemokines IP-10, Mig, and I-TAC are expressed by activated human bronchial epithelial cells. *J Immunol* 1999; **162**: 3549-3558 [PMID: 10092813]
- 52 **Lal N**, White BS, Goussous G, Pickles O, Mason MJ, Beggs AD, Tanieri P, Willcox BE, Guinney J, Middleton GW. KRAS Mutation and Consensus Molecular Subtypes 2 and 3 Are Independently Associated with Reduced Immune Infiltration and Reactivity in Colorectal Cancer. *Clin Cancer Res* 2018; **24**: 224-233 [PMID: 29061646 DOI: 10.1158/1078-0432.CCR-17-1090]
- 53 **Kistner L**, Doll D, Holtorf A, Nitsche U, Janssen KP. Interferon-inducible CXC-chemokines are crucial immune modulators and survival predictors in colorectal cancer. *Oncotarget* 2017; **8**: 89998-90012 [PMID: 29163806 DOI: 10.18632/oncotarget.21286]
- 54 **Zumwalt TJ**, Arnold M, Goel A, Boland CR. Active secretion of CXCL10 and CCL5 from colorectal cancer microenvironments associates with GranzymeB+ CD8+ T-cell infiltration. *Oncotarget* 2015; **6**: 2981-2991 [PMID: 25671296 DOI: 10.18632/oncotarget.3205]
- 55 **Wu Z**, Huang X, Han X, Li Z, Zhu Q, Yan J, Yu S, Jin Z, Wang Z, Zheng Q, Wang Y. The chemokine CXCL9 expression is associated with better prognosis for colorectal carcinoma patients. *Biomed Pharmacother* 2016; **78**: 8-13 [PMID: 26898419 DOI: 10.1016/j.biopha.2015.12.021]
- 56 **Agesen TH**, Sveen A, Merok MA, Lind GE, Nesbakken A, Skotheim RI, Lothe RA. ColoGuideEx: a robust gene classifier specific for stage II colorectal cancer prognosis. *Gut* 2012; **61**: 1560-1567 [PMID: 22213796 DOI: 10.1136/gutjnl-2011-301179]
- 57 **Wu Z**, Han X, Yan J, Pan Y, Gong J, Di J, Cheng Z, Jin Z, Wang Z, Zheng Q, Wang Y. The prognostic significance of chemokine receptor CXCR3 expression in colorectal carcinoma. *Biomed Pharmacother* 2012; **66**: 373-377 [PMID: 22401929 DOI: 10.1016/j.biopha.2011.12.003]
- 58 **Zeng YJ**, Lai W, Wu H, Liu L, Xu HY, Wang J, Chu ZH. Neuroendocrine-like cells -derived CXCL10 and CXCL11 induce the infiltration of tumor-associated macrophage leading to the poor prognosis of colorectal cancer. *Oncotarget* 2016; **7**: 27394-27407 [PMID: 27034164 DOI: 10.18632/oncotarget.8423]
- 59 **Brackett CM**, Kojouharov B, Veith J, Greene KF, Burdelya LG, Gollnick SO, Abrams SI, Gudkov AV. Toll-like receptor-5 agonist, entolimod, suppresses metastasis and induces immunity by stimulating an NK-dendritic-CD8+ T-cell axis. *Proc Natl Acad Sci USA* 2016; **113**: E874-E883 [PMID: 26831100 DOI: 10.1073/pnas.1521359113]
- 60 **Yang H**, Yamazaki T, Pietrocola F, Zhou H, Zitvogel L, Ma Y, Kroemer G. STAT3 Inhibition Enhances the Therapeutic Efficacy of Immunogenic Chemotherapy by Stimulating Type 1 Interferon Production by Cancer Cells. *Cancer Res* 2015; **75**: 3812-3822 [PMID: 26208907 DOI: 10.1158/0008-5472.CAN-15-1122]
- 61 **Akeus P**, Langenes V, Kristensen J, von Mentzer A, Sparwasser T, Raghavan S, Quiding-Järbrink M. Treg-cell depletion promotes chemokine production and accumulation of CXCR3(+) conventional T cells in intestinal tumors. *Eur J Immunol* 2015; **45**: 1654-1666 [PMID: 25754875 DOI: 10.1002/eji.201445058]
- 62 **Murakami T**, Kawada K, Iwamoto M, Akagami M, Hida K, Nakanishi Y, Kanda K, Kawada M, Seno H, Taketo MM, Sakai Y. The role of CXCR3 and CXCR4 in colorectal cancer metastasis. *Int J Cancer* 2013; **132**: 276-287 [PMID: 22689289 DOI: 10.1002/ijc.27670]
- 63 **Rupertus K**, Sinistra J, Scheuer C, Nickels RM, Schilling MK, Menger MD, Kollmar O. Interaction of the chemokines I-TAC (CXCL11) and SDF-1 (CXCL12) in the regulation of tumor angiogenesis of colorectal cancer. *Clin Exp Metastasis* 2014; **31**: 447-459 [PMID: 24493023 DOI: 10.1007/s10585-014-9639-4]
- 64 **Agostini M**, Janssen KP, Kim IJ, D'Angelo E, Pizzini S, Zangrando A, Zanon C, Pastrello C, Maretto I, Digito M, Bedin C, Jurisica I, Rizzolio F, Giordano A, Bortoluzzi S, Nitti D, Pucciarelli S. An integrative approach for the identification of prognostic and predictive biomarkers in rectal cancer. *Oncotarget* 2015; **6**: 32561-32574 [PMID: 26359356 DOI: 10.18632/oncotarget.4935]
- 65 **Li C**, Wang Z, Liu F, Zhu J, Yang L, Cai G, Zhang Z, Huang W, Cai S, Xu Y. CXCL10 mRNA expression predicts response to neoadjuvant chemoradiotherapy in rectal cancer patients. *Tumour Biol* 2014; **35**: 9683-9691 [PMID: 24969558 DOI: 10.1007/s13277-014-2234-0]
- 66 **Zhang Y**, Gao J, Wang X, Deng S, Ye H, Guan W, Wu M, Zhu S, Yu Y, Han W. CXCL4 mediates tumor regrowth after chemotherapy by suppression of antitumor immunity. *Cancer Biol Ther* 2015; **16**: 1775-1783 [PMID: 26479470 DOI: 10.1080/15384047.2015.1095404]
- 67 **Meijer J**, Zeelenberg IS, Sipos B, Roos E. The CXCR5 chemokine receptor is expressed by carcinoma cells and promotes growth of colon carcinoma in the liver. *Cancer Res* 2006; **66**: 9576-9582 [PMID: 17018614 DOI: 10.1158/0008-5472.CAN-06-1507]
- 68 **Zhu Z**, Zhang X, Guo H, Fu L, Pan G, Sun Y. CXCL13-CXCR5 axis promotes the growth and invasion of colon cancer cells via PI3K/AKT pathway. *Mol Cell Biochem* 2015; **400**: 287-295 [PMID: 25476740 DOI: 10.1007/s11010-014-2285-y]
- 69 **Olsen RS**, Nijm J, Andersson RE, Dimberg J, Wågsäter D. Circulating inflammatory factors associated with worse long-term prognosis in colorectal cancer. *World J Gastroenterol* 2017; **23**: 6212-6219 [PMID: 28974887 DOI: 10.3748/wjg.v23.i34.6212]
- 70 **Qi XW**, Xia SH, Yin Y, Jin LF, Pu Y, Hua D, Wu HR. Expression features of CXCR5 and its ligand, CXCL13 associated with poor prognosis of advanced colorectal cancer. *Eur Rev Med Pharmacol Sci* 2014; **18**: 1916-1924 [PMID: 25010623]
- 71 **Cremonesi E**, Governa V, Garzon JFG, Mele V, Amicarella F, Muraro MG, Trella E, Galati-Fournier V, Oertli D, Däster SR, Droeser RA, Weixler B, Bolli M, Rosso R, Nitsche U, Khanna N, Egli A, Keck S, Slotta-Huspenina J, Terracciano LM, Zajac P, Spagnoli GC, Eppenberger-Castori S, Janssen KP, Borsig L, Iezzi G. Gut microbiota modulate T cell trafficking into human colorectal cancer. *Gut* 2018; **67**: 1984-1994 [PMID: 29437871 DOI: 10.1136/gutjnl-2016-313498]
- 72 **Bindea G**, Mlecnik B, Tosolini M, Kirilovsky A, Waldner M, Obenaus AC, Angell H, Fredriksen T, Lafontaine L, Berger A, Bruneval P, Fridman WH, Becker C, Pagès F, Speicher MR, Trajanoski Z, Galon J. Spatiotemporal dynamics of intratumoral immune cells reveal the immune landscape in human cancer. *Immunity* 2013; **39**: 782-795 [PMID: 24138885 DOI: 10.1016/j.immuni.2013.10.003]
- 73 **Xing J**, Zhang C, Yang X, Wang S, Wang Z, Li X, Yu E. CXCR5⁺CD8⁺ T cells infiltrate the colorectal tumors and nearby lymph nodes, and are associated with enhanced IgG response in B cells. *Exp Cell Res* 2017; **356**: 57-63 [PMID: 28412245 DOI: 10.1016/j.yexcr.2017.04.014]
- 74 **Rachidi SM**, Qin T, Sun S, Zheng WJ, Li Z. Molecular profiling of multiple human cancers defines an inflammatory cancer-associated molecular pattern and uncovers KPNA2 as a uniform poor prognostic cancer marker. *PLoS One* 2013; **8**: e57911 [PMID: 23536776 DOI: 10.1371/journal.pone.0057911]
- 75 **Griffith JW**, Sokol CL, Luster AD. Chemokines and chemokine receptors: positioning cells for host defense and immunity. *Annu Rev Immunol* 2014; **32**: 659-702 [PMID: 24655300 DOI: 10.1146/annurev-immunol-032713-120145]

- 76 **Schramme A**, Abdel-Bakky MS, Kämpfer-Kolb N, Pfeilschifter J, Gutwein P. The role of CXCL16 and its processing metalloproteinases ADAM10 and ADAM17 in the proliferation and migration of human mesangial cells. *Biochem Biophys Res Commun* 2008; **370**: 311-316 [PMID: 18373975 DOI: 10.1016/j.bbrc.2008.03.088]
- 77 **Yu X**, Zhao R, Lin S, Bai X, Zhang L, Yuan S, Sun L. CXCL16 induces angiogenesis in autocrine signaling pathway involving hypoxia-inducible factor 1 α in human umbilical vein endothelial cells. *Oncol Rep* 2016; **35**: 1557-1565 [PMID: 26707275 DOI: 10.3892/or.2015.4520]
- 78 **Chung S**, Dwabe S, Elshimali Y, Sukhija H, Aroh C, Vadgama JV. Identification of Novel Biomarkers for Metastatic Colorectal Cancer Using Angiogenesis-Antibody Array and Intracellular Signaling Array. *PLoS One* 2015; **10**: e0134948 [PMID: 26258407 DOI: 10.1371/journal.pone.0134948]
- 79 **Kee JY**, Ito A, Hojo S, Hashimoto I, Igarashi Y, Tsuneyama K, Tsukada K, Irimura T, Shibahara N, Takasaki I, Inujima A, Nakayama T, Yoshie O, Sakurai H, Saiki I, Koizumi K. CXCL16 suppresses liver metastasis of colorectal cancer by promoting TNF- α -induced apoptosis by tumor-associated macrophages. *BMC Cancer* 2014; **14**: 949 [PMID: 25495942 DOI: 10.1186/1471-2407-14-949]
- 80 **Kee JY**, Ito A, Hojo S, Hashimoto I, Igarashi Y, Tsukada K, Irimura T, Shibahara N, Nakayama T, Yoshie O, Sakurai H, Saiki I, Koizumi K. Chemokine CXCL16 suppresses liver metastasis of colorectal cancer via augmentation of tumor-infiltrating natural killer T cells in a murine model. *Oncol Rep* 2013; **29**: 975-982 [PMID: 23242131 DOI: 10.3892/or.2012.2185]
- 81 **Matsushita K**, Toiyama Y, Tanaka K, Saigusa S, Hiro J, Uchida K, Inoue Y, Kusunoki M. Soluble CXCL16 in preoperative serum is a novel prognostic marker and predicts recurrence of liver metastases in colorectal cancer patients. *Ann Surg Oncol* 2012; **19** Suppl 3: S518-S527 [PMID: 21845497 DOI: 10.1245/s10434-011-1993-8]
- 82 **Lee WY**, Wang CJ, Lin TY, Hsiao CL, Luo CW. CXCL17, an orphan chemokine, acts as a novel angiogenic and anti-inflammatory factor. *Am J Physiol Endocrinol Metab* 2013; **304**: E32-E40 [PMID: 23115081 DOI: 10.1152/ajpendo.00083.2012]
- 83 **Maravillas-Montero JL**, Burkhardt AM, Hevezi PA, Carnevale CD, Smit MJ, Zlotnik A. Cutting edge: GPR35/CXCR8 is the receptor of the mucosal chemokine CXCL17. *J Immunol* 2015; **194**: 29-33 [PMID: 25411203 DOI: 10.4049/jimmunol.1401704]
- 84 **Weinstein EJ**, Head R, Griggs DW, Sun D, Evans RJ, Swearingen ML, Westlin MM, Mazzearella R. VCC-1, a novel chemokine, promotes tumor growth. *Biochem Biophys Res Commun* 2006; **350**: 74-81 [PMID: 16989774 DOI: 10.1016/j.bbrc.2006.08.194]
- 85 **Mu X**, Chen Y, Wang S, Huang X, Pan H, Li M. Overexpression of VCC-1 gene in human hepatocellular carcinoma cells promotes cell proliferation and invasion. *Acta Biochim Biophys Sin* (Shanghai) 2009; **41**: 631-637 [PMID: 19657564]
- 86 **Matsui A**, Yokoo H, Negishi Y, Endo-Takahashi Y, Chun NA, Kadouchi I, Suzuki R, Maruyama K, Aramaki Y, Semba K, Kobayashi E, Takahashi M, Murakami T. CXCL17 expression by tumor cells recruits CD11b+Gr1 high F4/80- cells and promotes tumor progression. *PLoS One* 2012; **7**: e44080 [PMID: 22952881 DOI: 10.1371/journal.pone.0044080]
- 87 **Ohlsson L**, Hammarström ML, Lindmark G, Hammarström S, Sitohy B. Ectopic expression of the chemokine CXCL17 in colon cancer cells. *Br J Cancer* 2016; **114**: 697-703 [PMID: 26889977 DOI: 10.1038/bjc.2016.4]
- 88 **Pagès F**, Mlecnik B, Marliot F, Bindea G, Ou FS, Bifulco C, Lugli A, Zlobec I, Rau TT, Berger MD, Nagtegaal ID, Vink-Börger E, Hartmann A, Geppert C, Kolwelter J, Merkel S, Grützmann R, Van den Eynde M, Jouret-Mourin A, Kartheuser A, Léonard D, Remue C, Wang JY, Bavi P, Roehrl MHA, Ohashi PS, Nguyen LT, Han S, MacGregor HL, Hafezi-Bakhtiari S, Wouters BG, Masucci GV, Andersson EK, Zavadova E, Vocka M, Spacek J, Petruzella L, Konopasek B, Dundr P, Skalova H, Nemejcova K, Botti G, Tatangelo F, Delrio P, Ciliberto G, Maio M, Laghi L, Grizzi F, Fredriksen T, Buttard B, Angelova M, Vasaturo A, Maby P, Church SE, Angell HK, Lafontaine L, Bruni D, El Sissy C, Haicheur N, Kirilovsky A, Berger A, Lagorce C, Meyers JP, Paustian C, Feng Z, Ballesteros-Merino C, Dijkstra J, van de Water C, van Lent-van Vliet S, Knijn N, Musinà AM, Scripcariu DV, Popivanova B, Xu M, Fujita T, Hazama S, Suzuki N, Nagano H, Okuno K, Torigoe T, Sato N, Furuhashi T, Takemasa I, Itoh K, Patel PS, Vora HH, Shah B, Patel JB, Rajvik KN, Pandya SJ, Shukla SN, Wang Y, Zhang G, Kawakami Y, Marincola FM, Ascierto PA, Sargent DJ, Fox BA, Galon J. International validation of the consensus Immunoscore for the classification of colon cancer: a prognostic and accuracy study. *Lancet* 2018; **391**: 2128-2139 [PMID: 29754777 DOI: 10.1016/S0140-6736(18)30789-X]

P- Reviewer: Kim SM, Mastoraki A, Nakayama Y, Popp C

S- Editor: Ma RY **L- Editor:** A **E- Editor:** Huang Y





Published by **Baishideng Publishing Group Inc**
7901 Stoneridge Drive, Suite 501, Pleasanton, CA 94588, USA
Telephone: +1-925-223-8242
Fax: +1-925-223-8243
E-mail: bpgoffice@wjgnet.com
Help Desk: <http://www.f6publishing.com/helpdesk>
<http://www.wjgnet.com>



ISSN 1007-9327

